Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

Cyclacel Pharmaceuticals, Inc.

  • Spiro Rombotis, Cyclacel Pharmaceuticals, Inc.

Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company developing innovative medicines targeting cell cycle, transcriptional regulation and DNA damage response molecules critical in oncogenesis/cancer progression. Cyclacel's lead transcriptional regulation program is evaluating a CDK inhibitor, CYC065 in CLL patients in combination with venetoclax. The DNA damage response program is evaluating a sequential regimen of sapacitabine and seliciclib, a CDK inhibitor, in patients with BRCA positive solid cancers. The safety/tolerability profile of CYC140, a Polo-like-kinase 1 inhibitor is being assessed in advanced cancer patients. Cyclacel envisions building a healthcare business focusing on an unmet medical need for patients in the hematology-oncology area.

  • Date:Tuesday, February 12
  • Time:10:15 AM - 10:30 AM
  • Room:Hudson/Empire
  • Location:7th Floor
  • Session Type:Company Presentation
  • Please submit your session questions in advance at:http://bit.ly/BIOCEO19question
  • Submission ID:23317
  • Company Presentation - Presentation Type:Publicly Traded Company
  • Goal for Presentation:Investor Update
  • Company Website:www.cyclacel.com
  • Company HQ City:Berkeley Heights
  • Company HQ State:New Jersey
  • Company HQ Country:United States
  • Ticker:CYCC
  • Exchange:NASDAQ
  • CEO/Top Company Official:Spiro Rombotis
  • Year Founded:1996
  • Main Therapeutic Focus:Oncology
  • Lead Product in Development:CYC065, sapacitabine, CYC140
  • Development Phase of Primary Product:Phase I
Speakers
Spiro Rombotis
Cyclacel Pharmaceuticals, Inc.
Back